AEON Biopharma, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity ​ Market Information ​ Our common stock trades on NYSE American under the symbol “AEON”. Trading of our common stock commenced on July 24, 2023 in connection with the consummation of our Merger. Prior to that time, there was no established public trading market for our common stock. ​ Holders ​ As of March 17, 2025, there were approximately 461 holders of record of our common stock. These numbers do not include beneficial owners whose shares were held in street name. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. ​ Dividends ​ The Company has never declared dividends on the Company’s equity securities, and currently does not plan to declare dividends on shares of the Company’s common stock in the foreseeable future. The Company expects to retain future earnings, if any, for use in the operation and expansion of the Company’s business. The payment of cash dividends in the future, if any, will be at the discretion of the Board and will depend upon such factors as earning levels, capital requirements, overall financial condition and any other factors deemed relevant by the Board. ​ Unregistered Sales of Equity Securities and Use of Proceeds During the fiscal year ended December 31, 2024, the Company did not make any unregistered issuances or sales of equity securities that were not reported in a Current Report on Form 8-K. Purchases of Equity Securities by the Issuer and Affiliated Purchasers None. ​ ​ Item 6. Reserved ​ ​ 75 Table of Contents